Merck & Co., Inc.

Equities

Market Closed - Nyse Other stock markets 04:00:18 2026-04-10 pm EDT			5-day change	1st Jan Change
121.42 ^USD	-1.03%		+0.46%	+15.35%

Apr. 09	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT
Apr. 08	Merck CEO Pay Falls 10% in 2025 Due to Lower Stock, Option Awards	DJ

Published on 03/03/2026 at 04:06 pm EST

S&P Capital IQ

Presenter Speech
Steve Scala (Analysts)

[Audio Gap]

46th Annual Healthcare Conference. We are absolutely delighted to have Merck senior leadership here with us today.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Apr. 09	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT
Apr. 08	Merck CEO Pay Falls 10% in 2025 Due to Lower Stock, Option Awards	DJ
Apr. 08	Merck & Co Inc CEO Robert M. Davis 2025 total compensation $20.8 million	RE
Apr. 08	Wolfe Research Adjusts PT on Merck & Co. to $150 From $142, Maintains Outperform Rating	MT
Apr. 07	Merck Begins $53 Per Share Tender Offer for Terns Pharmaceuticals	MT
Apr. 07	Merck begins tender offer to acquire Terns Pharmaceuticals, Inc.	RE
Apr. 06	JPMorgan Adjusts Price Target on Merck & Co. to $135 From $125, Maintains Overweight Rating	MT
Apr. 02	Merck Announces European Commission Approves KEYTRUDA (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS =1) Platinum-Resistant Recurrent Ovarian Carcinoma	CI
Apr. 02	Merck Announces Initiation of Pivotal Phase 2B/3 Trial Evaluating Mk-8748 for Treatment of Neovascular Age-Related Macular Degeneration	CI
Apr. 02	Merck Says EU Approves Keytruda Combination Regimen for Platinum-Resistant Ovarian Cancer	MT
Apr. 02	Merck Starts Phase 2b/3 Trial of Neovascular Age-Related Macular Degeneration Treatment	MT
Apr. 02	US Set to Impose 100% Tariffs on Some Drug Imports	MT
Apr. 01	Trump administration readies new tariffs on select drugmakers, Bloomberg News reports	RE
Mar. 31	Infinimmune, Merck enter into antibody discovery pact	RE
Mar. 31	Infinimmune enters collaboration with Merck to discover novel human antibody therapeutics	RE